Sign In
Buy CPRX
$31.49
+0 (+0%)
At Close: Jul 31, 2026
Should Value Investors Buy Catalyst Pharmaceuticals (CPRX) Stock?
10:40am, Wednesday, 17'th Dec 2025
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest
Catalyst Pharmaceuticals to Participate in the 44th Annual J.P. Morgan Healthcare Conference
08:03am, Monday, 15'th Dec 2025
CORAL GABLES, Fla., Dec. 15, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, de
Catalyst Pharmaceuticals, Inc. (CPRX) Presents at BofA Securities CNS Therapeutics Virtual Conference 2025 Transcript
04:07pm, Monday, 08'th Dec 2025
Catalyst Pharmaceuticals, Inc. (CPRX) Presents at BofA Securities CNS Therapeutics Virtual Conference 2025 Transcript
Catalyst (CPRX) Up 10% Since Last Earnings Report: Can It Continue?
12:36pm, Friday, 05'th Dec 2025
Catalyst (CPRX) reported earnings 30 days ago. What's next for the stock?
Catalyst Pharmaceutical (CPRX) Recently Broke Out Above the 20-Day Moving Average
10:35am, Thursday, 04'th Dec 2025
From a technical perspective, Catalyst Pharmaceutical (CPRX) is looking like an interesting pick, as it just reached a key level of support. CPRX recently overtook the 20-day moving average, and this
Catalyst Pharmaceuticals, Inc. (CPRX) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
04:43pm, Tuesday, 02'nd Dec 2025
Catalyst Pharmaceuticals, Inc. (CPRX) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Why Catalyst Pharmaceutical (CPRX) is a Top Momentum Stock for the Long-Term
10:52am, Tuesday, 02'nd Dec 2025
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
CPRX or DSNKY: Which Is the Better Value Stock Right Now?
12:48pm, Monday, 01'st Dec 2025
Investors looking for stocks in the Medical - Drugs sector might want to consider either Catalyst Pharmaceutical (CPRX) or Daiichi Sankyo Co., Ltd. - Sponsored ADR (DSNKY).
Wall Street Analysts Think Catalyst (CPRX) Could Surge 47.37%: Read This Before Placing a Bet
10:56am, Monday, 01'st Dec 2025
The mean of analysts' price targets for Catalyst (CPRX) points to a 47.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analyst
Should Value Investors Buy Catalyst Pharmaceuticals (CPRX) Stock?
10:41am, Monday, 01'st Dec 2025
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest
Boston Partners Has $27.93 Million Stock Position in Catalyst Pharmaceuticals, Inc. $CPRX
04:04am, Friday, 28'th Nov 2025
Boston Partners raised its stake in Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) by 0.6% in the undefined quarter, according to the company in its most recent disclosure with the Securities and Excha
Catalyst Pharmaceuticals to Participate in the Bank of America CNS Therapeutics Virtual Conference
08:03am, Monday, 24'th Nov 2025
CORAL GABLES, Fla., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, dev
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Given Consensus Rating of “Buy” by Brokerages
03:46am, Saturday, 22'nd Nov 2025
Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX - Get Free Report) have received an average rating of "Buy" from the ten brokerages that are covering the firm, MarketBeat.com reports. Two inves
Here's Why Catalyst Pharmaceutical (CPRX) is a Strong Value Stock
10:46am, Wednesday, 19'th Nov 2025
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Catalyst Pharmaceuticals Recognized as One of North America's Fastest-Growing Companies on the 2025 Deloitte Technology Fast 500™
08:03am, Wednesday, 19'th Nov 2025
Attributes 249% Revenue Growth to Portfolio Momentum and Focused Execution Attributes 249% Revenue Growth to Portfolio Momentum and Focused Execution
